Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108Phase 2Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jun 2024
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in invasive lobular carcinoma (ILC), sponsored by Vanderbilt-Ingram Cancer Center. Started Jun 2024; status: recruiting.
02
Drugs
neratinib
03
Conditions
invasive lobular carcinoma (ILC)
Beyond the preview
Go deeper on NCT05919108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919108.